TP53 and breast cancer: These findings are consistent with those of previous reports that RAD6 levels are increased in breast cancer and mediate the addition of one (mono) to two (multimono) ubiquitin molecules on p53, forming a RAD6–p53–p14ARF complex and that p53 modifications are important damage-induced responses following chemotherapy [25,26,27].